Leven, Anna-Sophia and Peters, Triinu and Rajcsanyi, Luisa Sophie and Weichenthal, Michael and Mohr, Peter and Meier, Friedegund and von Wasielewski, Imke and Gutzmer, Ralf and Utikal, Jochen and Terheyden, Patrick and Herbst, Rudolf and Haferkamp, Sebastian and Pfoehler, Claudia and Leiter, Ulrike and Forschner, Andrea and Kreuter, Alexander and Gebhardt, Christoffer and Lutze, Stine and Weishaupt, Carsten and Grabbe, Stephan and Debus, Dirk and Hassel, Jessica and Welzel, Julia and Heinzerling, Lucie and Berking, Carola and Loquai, Carmen and Gambichler, Thilo and Ziemer, Mirjana and Becker, Juergen C. and Tasdogan, Alpaslan and Zimmer, Lisa and Livingstone, Elisabeth and Schadendorf, Dirk and Roesch, Alexander and Hinney, Anke and Ugurel, Selma (2025) Sex-specific survival in advanced metastatic melanoma-a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG. EUROPEAN JOURNAL OF CANCER, 227: 115668. ISSN 0959-8049, 1879-0852
Full text not available from this repository. (Request a copy)Abstract
Background: Females and males differ in their innate and acquired immune responses. Thus, it is hypothesized that the efficacy of anti-tumor immunotherapies may differ by sex. This study aimed to investigate sex-specific survival differences upon different therapy types in metastatic melanoma. Patients and Methods: Patients with unresectable metastatic melanoma (stage IV, AJCCv8) of the skin or unknown primary, who had received first-line PD-1-based immune checkpoint inhibition (ICI) or BRAF/MEK-directed targeted therapy (TT) were identified from the prospective multicenter DeCOG skin cancer registry ADOREG. Study endpoints were progression-free survival (PFS) and overall survival (OS). Results: A total of 2032 patients, 1274 males (62.7 %) and 758 females (37.3 %), received ICI (n = 1484) or TT (n = 548) between May 2010 and December 2020. At median follow-up of 28.6 months, no significant sex-specific differences in survival could be detected, neither in the total cohort nor by treatment type: PFS (total, p = 0.86; ICI, p = 0.46; TT, p = 0.21), OS (total, p = 0.60; ICI, p = 0.20; TT, p = 0.30). Multivariable Cox regression analyses also did not show a relevant prognostic influence by sex. Subgroup analyses were performed according to ICI therapy type. In n = 872 patients treated with PD-1 monotherapy, a survival advantage (PFS, p = 0.041; OS, p = 0.07) could be detected for males by univariable and multivariable analyses, whereas no sex-specific survival differences were found for n = 456 patients who received combination immunotherapy. Conclusion: No overall sex-specific survival differences were detected for metastatic melanoma patients in the first-line therapy setting. According to subgroup analyses males show a trend towards a survival advantage over females.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; Melanoma; Sex; Targeted therapy; Immune checkpoint inhibition therapy; Survival |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 24 Mar 2026 12:57 |
| Last Modified: | 24 Mar 2026 12:57 |
| URI: | https://pred.uni-regensburg.de/id/eprint/68068 |
Actions (login required)
 |
View Item |
